0001209191-19-034804.txt : 20190605
0001209191-19-034804.hdr.sgml : 20190605
20190605170607
ACCESSION NUMBER: 0001209191-19-034804
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190603
FILED AS OF DATE: 20190605
DATE AS OF CHANGE: 20190605
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wolff Henry Ward
CENTRAL INDEX KEY: 0001302390
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35935
FILM NUMBER: 19880532
MAIL ADDRESS:
STREET 1: 6701 KAISER DRIVE
CITY: FREMONT
STATE: CA
ZIP: 94555
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PORTOLA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001269021
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 270 EAST GRAND AVENUE, SUITE 22
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-244-6864
MAIL ADDRESS:
STREET 1: 270 EAST GRAND AVENUE, SUITE 22
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-06-03
0
0001269021
PORTOLA PHARMACEUTICALS INC
PTLA
0001302390
Wolff Henry Ward
C/O PORTOLA PHARMACEUTICALS, INC.
270 EAST GRAND AVE.
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Common Stock
2019-06-03
4
M
0
2000
27.5519
D
0
I
By Henry & Marian Wolff 1999 Revocable Trust
Common Stock
13766
D
Subsequent to Reporting Person's acquisition of 5,000 shares through a cash exercise on March 12, 2019, Reporting Person transferred 2,000 shares into the Henry & Marian Wolff 1999 Revocable Trust for which Reporting Person is a trustee.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2019.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.13 to $27.98, inclusive. The Reporting Person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Mike Ouimette, as attorney-in-fact
2019-06-05